+

WO1993014077A1 - Derives d'acide piperidineacetique servant d'inhibiteurs de l'agregation plaquettaire sanguine dependante du fibrinogene - Google Patents

Derives d'acide piperidineacetique servant d'inhibiteurs de l'agregation plaquettaire sanguine dependante du fibrinogene Download PDF

Info

Publication number
WO1993014077A1
WO1993014077A1 PCT/EP1993/000100 EP9300100W WO9314077A1 WO 1993014077 A1 WO1993014077 A1 WO 1993014077A1 EP 9300100 W EP9300100 W EP 9300100W WO 9314077 A1 WO9314077 A1 WO 9314077A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
piperazinyl
solvates
physiologically acceptable
acceptable salts
Prior art date
Application number
PCT/EP1993/000100
Other languages
English (en)
Inventor
Barry Porter
Colin David Eldred
Brian David Judkins
Henry Anderson Kelly
James Russell Wheatcroft
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929201171A external-priority patent/GB9201171D0/en
Priority claimed from GB929206004A external-priority patent/GB9206004D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to JP5512158A priority Critical patent/JPH07503459A/ja
Priority to EP93902223A priority patent/EP0623120A1/fr
Publication of WO1993014077A1 publication Critical patent/WO1993014077A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Definitions

  • This invention relates to acetic acid derivatives, to processes for their preparation, to pharmaceutical compositions containing such compounds and to their use in medicine.
  • glycoprotein complex Gp Ilb/IIIa is the fibrinogen binding site on platelets that mediates the adhesive function required for platelet aggregation and thrombus formation.
  • X 1 and Y 1 which may be the same or different, represent CH or N;
  • X 2 represents CH or, when X 1 represents CH, may also represent N;
  • Y 2 represents N or, when Y 1 represents N, may also represent CH;
  • Z represents N or N + R 5 ;
  • R 1 represents a hydrogen atom or a hydroxyl, C 1-4 alkyl or 2,2,2- trifluoroethyl group
  • R 2 represents a hydrogen atom or, when both X 1 and X 2 represent CH, may also represent a fluorine, chlorine or bromine atom or a C 1-4 alkyl group;
  • R 3 represents a hydrogen atom or, when both Y 1 and Y 2 represent N, may also represent a C 1-4 alkyl or hydroxymethyl group;
  • R 4 represents a hydrogen atom or , when Z represents N, R 4 may also represent a C 1-4 alkyl group;
  • R 5 represents a C 1-4 alkyl or phenyl C 1-4 alkyl group;
  • R 6 represents a naphthyl group; a thiophenyl group; an unsubstituted phenyl group; a phenyl group substituted by C 1-4 alkyl, C 1-4 alkoxy, phenyl C 1-3 alkoxy, OH, halogen, where halogen is fluorine, chlorine, bromine or iodine, CF 3 , unsubstituted phenyl, phenyl substituted by OH, pyridinyl, NR 7 R 8 , NHSO 2 R 7 , CONR 7 R 8 or CO 2 R 7 ; a C 1-4 alkyl group substituted by one or more naphthyl, phenyl, OH or CO 2 R 7 ; a C 2-4 alkenyl group substituted by one or more naphthyl, phenyl, OH or CO 2 R 7 ; or a saturated or unsaturated C 5-7 cycloalkyl group; and
  • R 7 and R 8 which may be the same or different represent H or C 1-4 aIkyl or, together with the nitrogen atom to which they are attached, form a saturated 5 to 7 membered ring.
  • salts referred to above will be the physiologically acceptable salts, but other salts may find use, for example in the preparation of compounds of formula (I) and the physiologically acceptable salts thereof.
  • the compounds of formula (I) contain at least one chiral centre (shown as * in formula (I)) and thus exist in the form of a pair of optical isomers (i.e. enantiomers).
  • the invention includes all such isomers and mixtures thereof including racemic mixtures.
  • Suitable physiologically acceptable salts of the compounds of formula (I) include acid addition salts formed with inorganic or organic acids (for example hydrochlorides, hydrobromides, sulphates, phosphates, benzoates, naphthoates, hydroxynaphthoates, p- toluenesulphonates, methanesulphonates, sulphamates, ascorbates, tartrates, salicylates, succinates, lactates, glutarates, glutaconates, acetates, tricarballylates, citrates, fumarates and maleates) and inorganic base salts such as alkali metal salts (for example sodium salts).
  • inorganic or organic acids for example hydrochlorides, hydrobromides, sulphates, phosphates, benzoates, naphthoates, hydroxynaphthoates, p- toluenesulphonates, methanesulphonates, sulphamates, as
  • the present invention encompasses all isomers of the compounds of formula (I) and their salts and solvates, including all tautomeric and optical forms, and mixtures thereof (e.g. racemic mixtures).
  • the present invention includes pharmacuetically acceptable derivatives of the compounds of formula (I).
  • pharmaceutically acceptable derivative is meant any pharmaceutically acceptable ester or salt or solvate of such ester of the compounds of formula (I) or any other compound which upon administration to the recipient is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof.
  • the compounds of formula (I) may be modified to provide pharmaceutically acceptable derivatives thereof at any of the functional groups in the compounds.
  • Such derivatives are compounds modified at the carboxyl or amidine functions.
  • compounds of interest include carboxylic acid esters of the compounds of formula (I).
  • esters include C 1-6 alkyl esters, more preferably C 1-3 alkyl esters, such as ethyl esters.
  • Other compounds of interest as pharmaceutically acceptable derivatives include benzoylamidine, alkyloxycarbonyl amidine and dialkyloxyphosphinyl amidine derivatives of the compounds of formula (I), which may be prepared by transformation of the amidine group.
  • carboxylic acid ester derivatives of formula (I) may be useful as intermediates in the preparation of compounds of formula (I), or as pharmaceutically acceptable derivatives of formula (I), or both.
  • the term 'alkyl' as a group or part of a group means a straight or branched chain alkyl group, for example a methyl, ethyl, n- propyl, i-propyl, n-butyl, s-butyl or t-butyl group.
  • X 1 and X 2 both represent CH;
  • Y 1 represents N
  • Z preferably represents N
  • R 1 represents a hydrogen atom or a hydroxyl group
  • R 1 most preferably represents a hydrogen atom
  • R 2 represents a hydrogen atom
  • R 3 represents a hydrogen atom
  • R 4 represents a hydrogen atom
  • R 6 represents a naphthyl group; a thiophenyl group; an unsubstituted phenyl group; a phenyl group substituted by C 1-4 alkoxy, phenyl C 1-3 alkoxy, OH, fluorine, bromine, CF 3 , unsubstituted phenyl, phenyl substituted by OH, pyridinyl, NH 2 , N(C 1-4 alkyl) 2 ,
  • R 6 most preferably represents an unsubstituted phenyl or a phenyl substituted in the 4- position by fluorine, bromine, CF 3 , unsubstituted phenyl, phenyl substituted by OH, pyridinyl, NH 2 , N(C 1-4 alkyl) 2 , NHSO 2 C 1-4 alkyl, CONR 7 R 8 (where R 7 and R 8 , together with the nitrogen atom to which they are attached, form a saturated 5 to 7 membered ring) or CO 2 H.
  • R 2 represents a chlorine or bromine atom or a C 1-4 alkyl group
  • R 2 is preferably in the position meta to the amidine function.
  • Particularly preferred compound of the invention are: 4-[4-[4-(Aminoiminomethyl)phenyl]-1-piperazinyl]- ⁇ -phenyl-1-piperidineacetic acid and physiologically acceptable salts and solvates thereof;
  • 1,1-Dimethylethyl 4-[4-[4-(aminoiminomethyl)phenyI]-1-piperazinyl]- ⁇ -(1- phenylethyl)-1-piperidineacetate and physiologically acceptable salts and solvates thereof; 4-[4-[4-(Aminoiminomethyl)phenyl]-1-piperazinyl]- ⁇ -(phenylethyl)-1- piperidineacetic acid and physiologically acceptable salts and solvates thereof;
  • the compounds of the present invention are of interest for use in human and veterinary medicine, particularly in the treatment or prophylaxis of thrombotic disorders.
  • thrombotic disorders include occlusive vascular diseases such as myocardial infarction, cardiac fatalities, angina, transient ischaemic attacks and thrombotic stroke, arteriosclerosis, vessel wall disease, peripheral vascular disease, nephropathy, retinopathy, postoperative thrombosis, pulmonary embolism, deep vein thrombosis and retinal vein thrombosis.
  • the compounds of the invention are also of interest for use in the
  • the compounds of the invention may also be useful for the treatment or prophylaxis of other conditions in which the glycoprotein complex Gp Ilb/IIIa or other integrin receptors are implicated.
  • the compounds of the invention may potentiate wound healing and be useful in the treatment of osteoporosis.
  • the compounds of the invention may also be useful for the treatment of certain cancerous diseases.
  • compounds of the invention may be of use to prevent or delay metastasis in cancer.
  • a compound of formula (I) or a physiologically acceptable salt or solvate thereof for use in human or veterinary medicine, particularly for use in the treatment or prophylaxis of thrombotic disorders.
  • a method of treating a human or animal subject suffering from or susceptible to a thrombotic disorder comprises administering to said subject an effective amount of a compound of formula (I) or a physiologically acceptable salt or solvate thereof.
  • the compounds of formula (I) may advantageously be used in conjunction with one or more other therapeutic agents.
  • suitable agents for adjunctive therapy include thrombolytic agents or any other compound stimulating thrombolysis or fibrinolysis and cytotoxic drugs. It is to be understood that the present invention covers the use of a compound of formula (I) or a physiologically acceptable salt or solvate thereof in combination with one or more other therapeutic agents.
  • compositions comprising a compound of formula (I) or a physiologically acceptable salt or solvate thereof adapted for use in human or veterinary medicine.
  • Such compositions may conveniently be presented for use in conventional manner in admixture with one or more physiologically acceptable carriers or excipients:
  • the compounds according to the invention may be formulated for administration in any suitable manner.
  • the compounds may, for example, be formulated for topical administration or administration by inhalation or, more preferably, for oral or parenteral administration.
  • the pharmaceutical composition may take the form of, for example, tablets, capsules, powders, solutions, syrups or suspensions prepared by conventional means with acceptable excipients.
  • the pharmaceutical composition may be given as an injection or a continuous infusion (e.g. intravenously, intravascularly or subcutaneously).
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
  • formulatory agents such as suspending, stabilising and/or dispersing agents.
  • For administration by injection these may take the form of a unit dose presentation or as a multidose presentation preferably with an added
  • the active ingredient may be in powder form for reconstitution with a suitable vehicle.
  • the compounds of the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the compounds of the invention may also be used in combination with other therapeutic agents.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a physiologically acceptable salt or solvate thereof together with another therapeutic agent, in particular a thrombolytic agent.
  • compositions comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention.
  • the individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.
  • a proposed daily dosage of a compound of formula (I) for the treatment of man is 0.01 mg/kg to 30 mg/kg, which may be conveniently administered in 1 to 4 doses.
  • the precise dose employed will depend on the age and condition of the patient and on the route of administration.
  • a daily dose of 0.1 mg/kg to lOmg/kg may be suitable for systemic administration.
  • alkylation e.g. ethylation
  • a suitable alkylating agent such as an alcoholic solvent (e.g. methanol) at an elevated temperature (e.g. reflux)
  • a source of ammonia e.g. ammonium acetate
  • a suitable solvent such as an alcoholic solvent (e.g. methanol) at an elevated temperature (e.g. reflux)
  • the alkylation may conveniently be effected by employing an appropriate trialkyloxonium salt (e.g. triethyloxonium tetrafluoroborate) in a suitable solvent (e.g. dichloromethane) at room temperature.
  • an appropriate trialkyloxonium salt e.g. triethyloxonium tetrafluoroborate
  • suitable solvent e.g. dichloromethane
  • methylation or benzylation may conveniently be effected using an alkyl or benzyl halide (e.g. iodomethane) in a suitable solvent such as a ketone (e.g. acetone) at an elevated temperature (e.g. reflux).
  • a suitable solvent such as a ketone (e.g. acetone)
  • an elevated temperature e.g. reflux
  • hydroxylamine or an acid addition salt thereof e.g. hydroxylamine hydrochloride
  • a suitable base such as an alkali or alkaline earth metal carbonate or bicarbonate (e.g. potassium carbonate) or an alkoxide such as potassium tert-butoxide and in a solvent such as an alcohol (e.g. methanol or tert-butanol), followed, where necessary, by removing any protecting groups present.
  • a suitable base such as an alkali or alkaline earth metal carbonate or bicarbonate (e.g. potassium carbonate) or an alkoxide such as potassium tert-butoxide and in a solvent such as an alcohol (e.g. methanol or tert-butanol), followed, where necessary, by removing any protecting groups present.
  • the reaction with hydroxylamine or an acid addition salt thereof may conveniently be effected at an elevated temperature (e.g. reflux) when a carbonate or bicarbonate is used.
  • an alkoxide the reaction
  • compounds of formula (I) in which R1 represents a hydroxyl, C 1-4 alkyl or 2,2,2-trifluoroethyl group may be prepared by treating compounds of formula (II) with a suitable alkylating agent as described in process (A) above followed by reaction of the in situ formed thioimidate with an amine R 1 NH 2 , (where R 1 represents hydroxyl, C 1-4 alkyl or 2,2,2-trifluoroethyl), with subsequent removal of the carboxylic acid protecting group.
  • the reaction with the amine R 1 NH 2 may conveniently be carried out in a suitable solvent such as an alcohol (e.g. methanol) or an ether (e.g.
  • compounds of formula (I) may also be prepared by reacting a compound of formula (IV) hereinafter with an alcohol (e.g.
  • compounds of formula (I) may be prepared by interconversion, utilising other compounds of formula (I) as precursors.
  • compounds of formula (I) in which R 1 represents a hydrogen atom may be prepared from corresponding compounds of formula (I) in which R 1 represents a hydroxyl group by catalytic hydrogenation in a solvent such as an alcohol (e.g. ethanol), or acetic acid preferably in the presence of acetic anhydride.
  • a solvent such as an alcohol (e.g. ethanol), or acetic acid preferably in the presence of acetic anhydride.
  • Suitable catalysts include Raney Nickel or conventional palladium, platinum or rhodium catalysts.
  • R 1 is hydrogen, C 1-4 alkyl or 2,2,2-trifluoroethyl
  • a platinum catalyst e.g. PtO 2
  • the reaction may conveniently be effected in a solvent such as an alcohol (e.g. ethanol), and optionally in the presence of an acid, such as hydrochloric acid.
  • Another process (G) for preparing compounds of formula (I) comprises
  • compounds of formula (I) may be prepared from protected carboxyl derivatives of compounds of formula (I).
  • Suitable carboxyl protection groups include, for example, those described in 'Protective Groups in Organic Synthesis' by Theodora W. Green, second edition, (John Wiley and Sons, 1991) which also describes methods for the removal of such groups.
  • carboxyl protecting groups include, for example, carboxylic acid ester groups such as carboxylic acid alkyl or aralkyl esters, for example where the alkyl or aralkyl portion of the ester function is methyl, ethyl, tert-butyl, methoxymethyl, benzyl, diphenylmethyl, triphenylmethyl or p-nitrobenzyl.
  • carboxylic acid ester groups such as carboxylic acid alkyl or aralkyl esters, for example where the alkyl or aralkyl portion of the ester function is methyl, ethyl, tert-butyl, methoxymethyl, benzyl, diphenylmethyl, triphenylmethyl or p-nitrobenzyl.
  • ester is an unbranched alkyl (e.g. methyl) ester deprotection may be effected under conditions of acid hydrolysis, for example using hydrochloric acid.
  • Tert-butyl and triphenylmethyl ester groups may be removed under conditions of moderate acid hydrolysis, for example using formic or trifluoroacetic acid at room temperature or using hydrochloric acid in acetic acid.
  • Benzyl, diphenylmethyl and nitrobenzyl ester groups may be removed by hydrogenolysis in the presence of a metal catalyst (e.g. palladium).
  • the required isomer may conveniently be separated using preparative high performance liquid chromatography (h.p.l.c.) applied to the final products of processes (A)-(G) above or applied prior to any final deprotection step in said processes.
  • preparative high performance liquid chromatography h.p.l.c.
  • reaction may conveniently be carried out in a solvent such as dimethylforrnamide or pyridine and in the presence of an organic base such as an amine (e.g. triethylamine).
  • a solvent such as dimethylforrnamide or pyridine
  • an organic base such as an amine (e.g. triethylamine).
  • Unprotected compounds of formula (III) may also be prepared from compounds of formula (IV) by removing the carboxylic acid protecting group R P according to the method described in process (E) hereinabove.
  • R 6 is as defined above or a protected derivative thereof but is not a benzyl or napthylmethyl group
  • a mixture of compounds of formulae (V) and (VI) may be treated with a reducing agent such as a metal borohydride in the presence of a suitable acid and in a suitable solvent at about room temperature.
  • a reducing agent such as a metal borohydride
  • the reduction may conveniently be carried out using sodium cyanoborohydride in a solvent such as an alcohol (e.g.
  • triacetoxyborohydride in a solvent such as tetrahydrofuran or dichloromethane in the presence of an acid (e.g. acetic acid).
  • an acid e.g. acetic acid
  • Compounds of formula (VI) may be prepared from an ⁇ -protected (e.g. ⁇ -benzyl protected) piperidin-4-one, optionally substituted by C 1-4 alkyl, by removal of the protecting group followed by treatment with a reagent LCHR 6 CO 2 R P (where R 6 is as defined in formula (VI) above and L is a leaving group, such as a halogen atom (e.g. bromine) or a sulphonate ester group (e.g. mesylate)).
  • a reagent LCHR 6 CO 2 R P where R 6 is as defined in formula (VI) above and L is a leaving group, such as a halogen atom (e.g. bromine) or a sulphonate ester group (e.g. mesylate)).
  • the removal of the protecting group may be effected by hydrogenolysis in the presence of a suitable transition metal catalyst such as a palladium catalyst (e.g pd(OH) 2 ).
  • a suitable transition metal catalyst such as a palladium catalyst (e.g pd(OH) 2 ).
  • compounds of formula (VI) in which R 6 represents a naphthyl, phenyl, naphthylC 2-4 alkyl or phenylC 2-4 alkyl group may be prepared by use of a reagent HalC ⁇ R 6 CO 2 R P (wherein R 6 represents a naphthyl, phenyl, naphthylC 2-4 alkyl or phenylC 2-4 alkyl group) as described above and preferably in the presence of a suitable base such as an alkali metal carbonate or bicarbonate (e.g. potassium carbonate) and in a solvent such as a nitrile (e.g. acetonitrile), conveniently at an elevated temperature (e.g. reflux).
  • a suitable base such as an alkali metal carbonate or bicarbonate (e.g. potassium carbonate)
  • a solvent such as a nitrile (e.g. acetonitrile)
  • the reagents of formula HalCHR 6 CO 2 R P are known compounds or may be prepared by either esterification of the corresponding ⁇ -halo carboxylic acid or by ⁇ -halogenation of the corresponding carboxylic acid ester, by standard methods.
  • the ⁇ -halo carboyxlic acids and the carboxylic acid esters above are known compounds or are readily prepared using conventional chemistry.
  • phenylC 1-3 alkoxy or protected hydroxy group or a halogen atom and RO 2 SO is a sulphonate ester group, such as a mesylate) as described above and preferably in the presence of a base such as an alkali metal hydrogen carbonate (e.g. sodium hydrogen carbonate) or carbonate (e.g. potassium carbonate).
  • a base such as an alkali metal hydrogen carbonate (e.g. sodium hydrogen carbonate) or carbonate (e.g. potassium carbonate).
  • the reaction is conveniently effectedin a polar, aprotic solvent, such as dimethylsulphoxide and preferably at elevated temperature (e.g. 80-100°C).
  • reagents of formula RO 2 SOCHR 6 CO 2 R P may be prepared from the corresponding ⁇ -hdyroxy carboxylic acids, under standard conditions.
  • ⁇ -Hydroxy carboxylic acids are known compounds or may be prepared by methods well known in the art.
  • R 6 is as defined in formula (VI) above
  • a base such as an alkali or alkaline earth metal carbonate or bicarbonate (e.g. sodium bicarbonate) and in a suitable solvent such as an aprotic polar solvent (e.g. dimethylformamide, acetonitrile or dimethylsulphoxide), conveniently at an elevated temperature.
  • a base such as an alkali or alkaline earth metal carbonate or bicarbonate (e.g. sodium bicarbonate) and in a suitable solvent such as an aprotic polar solvent (e.g. dimethylformamide, acetonitrile or dimethylsulphoxide), conveniently at an elevated temperature.
  • aprotic polar solvent e.g. dimethylformamide, acetonitrile or dimethylsulphoxide
  • Compounds of formula (VIII) may be prepared from compounds of formula (NI) by reacting said compounds of formula (VI) with a suitable piperazine derivative, optionally protected (e.g. ⁇ -benzyl protected), under reducing conditions, for example as described above for the reaction between compounds of formulae (V) and (VI), followed, where appropriate, by the removal of any ⁇ -protecting group present using conventional conditions, for example as described above.
  • a suitable piperazine derivative optionally protected (e.g. ⁇ -benzyl protected)
  • reducing conditions for example as described above for the reaction between compounds of formulae (V) and (VI)
  • R 6 is as defined in formula (VI) above
  • Compounds of formula (XI) may be prepared by reacting a 4- halopyridine derivative with 4-pyridylboronic acid, preferably in the presence of a suitable transition metal catalyst such as a palladium catalyst [e.g. tetrakis(triphenylphosphine)palladium(0)] and a suitable base such as an alkali metal carbonate (e.g. sodium carbonate).
  • a suitable transition metal catalyst such as a palladium catalyst [e.g. tetrakis(triphenylphosphine)palladium(0)]
  • a suitable base such as an alkali metal carbonate (e.g. sodium carbonate).
  • the reaction may conveniently be effected in a solvent such as an aqueous ether (e.g. aqueous 1,2-ethanediol dimethyl ether).
  • Compounds of formula (XV) may be prepared by reacting a suitable 4-halopyridine with a suitable piperazine under the conditions described above for preparing compounds of formula (IV) from compounds of formula (VII).
  • Suitable bases include alkali or alkaline earth metal carbonates or bicarbonates such as sodium bicarbonate or potassium carbonate.
  • the reaction may conveniently be effected in a solvent such as
  • dimethylformamide or dimethylsulphoxide at an elevated temperature e.g. 100°-200°C.
  • compounds of formula (XVI) are treated with benzyl bromide in an alcoholic solvent (e.g. ethanol) or a halogenated hydrocarbon (e.g. dichloromethane) at an elevated temperature to provide a salt of formula (XVII)
  • an alcoholic solvent e.g. ethanol
  • a halogenated hydrocarbon e.g. dichloromethane
  • borohydride reducing agent such as sodium borohydride in a suitable solvent such as an alcohol (e.g. ethanol) or dimethylformamide or a mixture of such solvents to a compound of formula (XVIII)
  • Removal of the benzyl group and reduction of the double bond from a compound of formula (XVIII) provides the desired compounds of formula (V).
  • the removal of the benzyl group may conveniently be effected by hydrogenolysis in the presence of a palladium catalyst such as Pd(OH) 2 -on-carbon, or by reaction with 1-chloroethyl chloroformate in the presence of a base such as 'proton sponge, followed by treatment with methanol.
  • the reduction of the double bond may conveniently be effected by hydrogenation in the presence of a platinum catalyst such as platinum-on-carbon or platinum oxide or a palladium catalyst such as palladium hydroxide-on-carbon and optionally in the presence of an acid (e.g. hydrochloric acid).
  • the compound of formula (XX) is a known compound described by W. J.
  • Alkylation may also be effected using a tin reagent R 4 Sn (where R is C 1-4 alkyl) in the presence of a palladium catalyst such as bis (triphenylphosphine)benzylpalladium chloride.
  • a palladium catalyst such as bis (triphenylphosphine)benzylpalladium chloride.
  • Compounds of formula (XXI) may be prepared by reacting compounds of formula (V) with an N-protected piperidin-4-one, optionally substituted by C 1-4 alkyl, under reducing conditions (for example as described above for the reaction between compounds of formulae (V) and (VI)), followed by removing the N-protecting group.
  • Suitable protecting groups include -CO 2 Alk (where Alk is an alkyl group such as t-butyl), or aralkyl, for example benzyl.
  • the former protecting group may be removed by acid hydrolysis (e.g. using trifluoroacetic acid at about room temperature), the latter under the conditions described above for the removal of the benzyl group from compounds of formula (XVIII).
  • reaction may conveniently be effected in a solvent such as an aromatic hydrocarbon (e.g. toluene) and preferably in the presence of alumina at an elevated temperature.
  • a solvent such as an aromatic hydrocarbon (e.g. toluene) and preferably in the presence of alumina at an elevated temperature.
  • Compounds of formula (XXII) may be prepared by reacting a 2,5- dihalopyridine (e.g. 2,5-dibromopyridine) with a compound of formula (VIII) or a compound of formula (XXIII),
  • a 2,5- dihalopyridine e.g. 2,5-dibromopyridine
  • reaction may conveniently be effected under the conditions described above for the reaction between compounds of formulae (VII) and (VIII).
  • Compounds of formula (XXIV) may be prepared by reacting a 2,5- dihalopyridine (e.g. 2,5-dibromopyridine) with a compound of formula (X) under the conditions described above for the reaction between compounds of formulae (VII) and (VIII).
  • a 2,5- dihalopyridine e.g. 2,5-dibromopyridine
  • Compounds of formula (XXV) may be prepared by reacting a 2,5- dihalopyridine (e.g. 2,5-dibromopyridine) with a compound of formula (XV) under the conditions described above for the reaction between compounds of formulae (VII) and (VIII).
  • a 2,5- dihalopyridine e.g. 2,5-dibromopyridine
  • Compounds of formula (XXVI) may be prepared by reacting a 2,5- dihalopyridine (e.g. 2,5-dibromopyridine) with a suitable piperazine derivative under the conditions described above for the reaction between compounds of formulae (VII) and (VIII).
  • a 2,5- dihalopyridine e.g. 2,5-dibromopyridine
  • a suitable piperazine derivative under the conditions described above for the reaction between compounds of formulae (VII) and (VIII).
  • Compounds of formula (XXVII) may be prepared by reacting a 2,5- dihalopyridine (e.g. 2,5-dibromopyridine) with a compound of formula (XX) under the boronic acid coupling conditions described previously.
  • a 2,5- dihalopyridine e.g. 2,5-dibromopyridine
  • a compound of formula (XX) under the boronic acid coupling conditions described previously.
  • Halopyridines and dihalopyridines described above are known in the art.
  • Alkyl substituted halopyridines are either known compounds described in Chem. Pharm. Bull., 1988, 36, 2244 and J. Het. Chem., 1988, 25, 81 or may be prepared according to the methods described therein.
  • a strong base such as a lithium amide (e.g. lithium bis(trimethylsilyl)amide or lithium diisopropylamide) at reduced temperature (e.g. -70°C) in a suitable solvent (e.g.
  • alkylation may be effected by using, for example, a benzyl or naphthylmethyl halide (e.g. benzyl or naphthylmethyl bromide).
  • a benzyl or naphthylmethyl halide e.g. benzyl or naphthylmethyl bromide
  • the desired stereochemistry of the product may be obtained either by commencing with an optically pure starting material or by resolving the racemic mixture at any convenient stage in the synthesis.
  • Resolution of the final product, an intermediate or a starting material may be effected by any suitable method known in the art: see for example Stereochemistry of Carbon Compounds' by E L Eliel (McGraw Hill, 1962) and 'Tables of Resolving Agents' by S H Wilen.
  • acids of formula (I) are isolated following work-up as acid addition salts, e.g. trifluoroacetate salts.
  • Physiologically acceptable acid addition salts of the compounds of formula (I) may be prepared from the corresponding trifluoroacetate salts by exchange of ion using conventional means, for example by neutralisation of the trifluoroacetate salt using a base such as aqueous sodium hydroxide, followed by addition of a suitable organic or inorganic acid.
  • Inorganic base salts of the compounds of formula (I) may also be prepared from the corresponding trifluoroacetate salts by addition of a suitable strong base such as sodium hydride.
  • Solvates e.g. hydrates of a compound of formula (I) may be formed during the work-up procedure of one of the aforementioned process steps.
  • 4,4'-Bipiperidine dihydrochloride (3.2g) was dissolved in dimethylsulphoxide (80ml), potassium carbonate (5.0g) added and the mixture heated at 130°C for 20min.
  • N-Benzyl-4-piperidone (10g) was dissolved in absolute ethanol (100ml), treated with dilute hydrochloric acid (2N; 29ml) and hydrogenated at room temperature and pressure over Pearlmann's catalyst (lg) for 18h.
  • the catalyst was removed by filtering through "hyflo” and the solvent was removed in vacuo to leave the title compound (8.59g).
  • Lithium bis(trimethylsilyl)amide (1M solution in tetrahydrofuran, 3.4ml) was added to a solution of intermediate 11 (1g) in dry tetrahydrofuran (25ml) at -72°C under nitrogen. The solution was stirred at -70°C for 15min. Benzyl bromide (0.309ml) in tetrahydrofuran (70ml) was added dropwise over 10min, and the solution was allowed to reach room temperature (18h). The solvent was removed in vacuo and saturated aqueous ammonium chloride (50ml) added.
  • dichloromethane 50ml was treated dropwise at 0°C with methanesulphonyl chloride (0.904ml). The mixture was stirred at room temperature under nitrogen for 1h. The mixture was poured into water (100ml) and the aqueous layer extracted with
  • Lithium diisopropylamide mono (tetrahydrofuran) complex (1.5M in cyclohexane, 29.6ml) was added to a stirred solution of ethyl 1- naphthaleneacetate (8g) in dry tetrahydrofuran (60 ml) at -70°, under nitrogen, and stirring was continued at -70° for 30 min.
  • Carbon tetrabromide (14.6ml) was added, the vessel removed from the cold bath and the mixture was stirred at room temperature for 2h.
  • Ammonium chloride (100 ml) was added and the solution extracted with ethyl acetate (3x150 ml).
  • Lithium diisopropylamide mono tetrahydrofuran complex (1.5 M in cyelohexane, 9.02ml) was added to a stirred solution of intermediate 11 (4.0g) in dry tetrahydrofuran (75ml) at -75°C under nitrogen and stirring was continued for 1h.
  • Chlorotitanium triisopropoxide (3.23ml) was added at -72°C and stirring was continued at -72°C for 30 mins.
  • Acetophenone (1.37ml) was added and the mixture stirred at -70°C for 30 mins and allowed to warm up to room temperature overnight (16h). The solvent was removed in vacuo to leave an orange solid, which was partitioned between dichloromethane
  • Lithium diisopropylamide mono tetrahydrofuran complex (1.5M in cyclohexane;
  • Methane sulphonyl chloride (0.26ml) was added at 0° under nitrogen to a stirred solution of the aniline (940mg) in pyridine (10ml). After 1.5h the orange solution was cooled to ca 15°C and more methane sulphonyl chloride (0.13ml) was added. After 30 min. saturated sodium bicarbonate (50ml) was added and the mixture evaporated to dryness. Water (50ml) and ethyl acetate (50ml) were added to the residue and the aqueous layer was extracted again with ethyl acetate (50ml). The combined organic extracts were washed with brine, dried (Na 2 SO 4 ) and evaporated to give an orange foam. Purification by column chromatography on silica gel (Merck 9385), eluting with 50-100% ethyl acetate in hexane gave the title compound as a yellow oil, (0.615mg).
  • Example 7 A solution of Example 7 (0.500g) in 2N hydrochloric acid was stirred at 60°C for 21 h and at 80°C for 3 days. The acid was removed in vacuo and the residue dissolved in a minimum volume of distilled water. Purification by gradient preparative h.p.l.c.
  • Example 9 (164mg) was dissolved in 2M hydrochloric acid (25ml) and the mixture heated at 80°C for 65 h. The solvent was removed in vacuo and the residue purified by preparative h.p.l.c (gradient profile 10-40% (ii) in 10 min and .40% (ii) isochratic for
  • Example 11 A solution of Example 11 (0.140g) in 2N hydrochloric acid (30ml) was heated at 80°C under nitrogen for 3 days and at 90°C for 24h. The mbcture was concentrated in vacuo and the residue dissolved in a minimum volume of water. Purification by preparative h.p.l.c. (gradient profile 5-20% (ii) in 10min and 20% (ii) isochratic for 8min) gave after R T 14 min the title compound as a white solid (0.0975g).
  • Example 12 (1.5g, crude) was treated with hydrochloric acid (5N, 150ml) and heated to 90°C for 18h. The mixture was concentrated in vacuo to leave a pale yellow solid which was purified by preparative h.p.l.c. (gradient profile 10-45% (ii) in 11min) to give after R t 10.5 min the title compound as a white solid (497mg).
  • hydroxylamine hydrochloride (82mg) and potassium t- butoxide (126mg) were added after 0, 2 and 4h while heating under reflux, under nitrogen. Heating under reflux was continued for 17h, the mixture was concentrated to 20ml and further hydroxylamine hydrochloride (85mg) and potassium t-butoxide (128mg) were added. Heating under reflux was continued for 8h before further reagents, as above, were added. After heating under reflux overnight the mixture was concentrated to ca. 5ml and poured into water (100ml). The precipitate was filtered off, dried in vacuo and triturated with hot toluene (20ml). After cooling to ca. 40°C, the mixture was filtered to afford the title compound (1.17g) as a white solid.
  • Example 8 (1.02g) was suspended in acetic acid (20ml) and acetic anhydride (0.8ml) added. The suspension was added to dry 10% palladium on carbon (800mg) in acetic acid
  • Example 10 A mixture of Example 10 (0.450g), acetic anhydride (0.352ml) and 10% palladium on carbon (50mg) in glacial acetic acid (10ml) was hydrogenated at room temperature and pressure for lh. The catalyst was filtered off and the filtrate concentrated in vacuo: the residue was partitioned between dichloromethane (100ml) and 2N sodium carbonate (100ml). The aqueous layer was extracted with dichloromethane (2x100ml), and the combined organic extracts were dried (anhydrous potassium carbonate) and evaporated in vacuo to afford a dark brown solid (0.808g). Purification by flash chromatography on silica gel (Merck 9385, eluting with system B 89:10:1, 70:30:3, and finally 50:50:1) gave the title compound as a light brown solid (0.143g).
  • Example 15 Acetic acid (8ml) containing acetic anhydride (0.57ml) was added to Example 13 (0.52g) and 10% palladium on carbon (75mg). The suspension was stirred under an atmosphere of hydrogen until uptake had ceased (1h). The suspension was filtered through hyflo and the filtrate evaporated in vacuo to give the title compound (0.5g). Analytical h.p.l.c. (gradient profile 10-90% (ii) in 25 min) R.9.7min. Example 15
  • Example 14 (ca 0.5g) was stirred in 5N hydrochloric acid (25ml) at 75° for 18h. The solvent was evaporated in vacuo and the residue purified by preparative h.p.l.c. (gradient profile 10-60% (ii) in 17min) to give after R T 12.1 min the title compound as a beige solid
  • Example 16 Acetic acid (10ml) containing acetic anhydride (0.324ml) was added to Example 16 (1.15g) and 10% palladium on carbon (150mg). The suspension was stirred under an atmosphere of hydrogen until uptake ceased (2h). The suspension was filtered through acid washed hyflo and the filtrate evaporated in vacuo to give the title compound as a red oil (0.8g).
  • Example 17 (0.8g) was stirred in 5N hydrochloric acid (25ml) at 90° for 24h. The solvent was evaporated in vacuo and the residue purified by preparative h.p.l.c. (gradient profile 10-60% (ii) in 17 min.) to give after R T 12.3 min the title compound as a beige solid (0.061g) Analysis Found C,50.7; H,4.8; N,9.1;
  • Example 20 4-[4-[4-[Aminoiminomethyl)phenyl]-1-piperazinyl]- ⁇ -(1-naphthalenyl)-1-piperidineacetic acid trifluoroacetate salt
  • Example 20 (1g) was stirred in 5N hydrochloric acid (20ml) at 90°C for 60h. The solvent was evaporated in vacuo and the residue purified by preparative h.p.l.c. (gradient profile 10-60% (ii) in 17 min) to give after R T 1 1.9 min the title compound as a beige solid (0.410g).
  • Example 22 A mixture of Example 22 (1g) acetic anhydride (0.786 ml) and 10% palladium on carbon (110mg) in acetic acid (25ml) was stirred under hydrogen for 1.75h. The catalyst was filtered off, the filtrate concentrated in vacuo and the residue partitioned between ethyl acetate (200ml) and 2N sodium carbonate (200ml). The aqueous layer was extracted with ethyl acetate (2x 100ml). The combined ethyl acetate extracts were washed with brine (250ml), dried (MgSO 4 ) and the solvent removed in vacuo to afford a brown solid. Purification by preparative h.p.l.c. (gradient profile 10-35% (ii) in 10 min and 35% (ii) isochratic for 8 min) gave after R T 11.5 min the title compound as a white solid (0.28g).
  • Example 23 A solution of Example 23 (0.250g) in 2N hydrochloric acid (100ml) was heated at 80-90°C under nitrogen for 3 days. The mixture was concentrated to ca 10ml in vacuo and purified by preparative h.p.l.c. (gradient profile 5-20% (ii) in 10 min and 20 (ii) isochratic for 8 min) to give after R t 13.8 min the title compound as an off white solid
  • Example 25 Acetic acid (10ml) containing acetic anhydride (0.2ml) was added to Example 25 (795mg) and 10% palladium on carbon (100mg). The suspension was stirred in a hydrogen atmosphere until hydrogen uptake ceased, the catalyst filtered off through a small pad of acetic acid washed hyflo, and the filtrate was evaporated to give a red-brown gum. Purification by preparative h.p.l.c. (gradient profile 10-55% (ii) in 17min,) gave after R T 14.9 min the title compound as a beige solid (482mg).
  • Example 26 A solution of Example 26 (480mg) in ethanol (15ml) and dimethylformamide (3 ml) was added to pre-reduced 10% palladium on carbon (100mg) in ethanol (6ml). The mixture was stirred in a hydrogen atmosphere at room temperature and atmospheric pressure for 3 hrs. The catalyst was removed by filtration through 'hyflo' and the filtrate evaporated to give the title compound as a beige solid (320mg).
  • Example 27 A solution of Example 27 (235mg) in hydrochloric acid (4N, 15ml) was stirred at 80°C for 30hrs, evaporated to dryness and the residue triturated with isopropanol to give the title compound as a pink solid (114mg).
  • Example 56 The title compound was prepared from Example 56 by a method analogous to that used for the preparation of Example 2 from Example 8 (via Example 9).
  • Example 58 4-[4-[4-(Aminoiminomethyl)phenyl]-1-piperazinyl]- ⁇ -(4-aminophenyl)-1- piperidineacetic acid
  • the title compound was prepared from Example 58 by a method analogous to that used for Example 57.
  • Inhibition of blood platelet aggregation by compounds of the invention was determined according to the following procedure. Citrated whole blood (1 part 3.8% trisodium citrate : 9 parts blood) was obtained from human volunteers, free of medication for at least 10 days prior to collection. The blood was incubated with 0.1 mM aspirin and 0.05 ⁇ M prostacyclin and then centrifuged at 1000g for 4 minutes (20°C). The supernatant platelet rich plasma (PRP) was further centrifuged at 1300g for 10 minutes (20°C) to sediment the platelets.
  • Citrated whole blood (1 part 3.8% trisodium citrate : 9 parts blood) was obtained from human volunteers, free of medication for at least 10 days prior to collection. The blood was incubated with 0.1 mM aspirin and 0.05 ⁇ M prostacyclin and then centrifuged at 1000g for 4 minutes (20°C). The supernatant platelet rich plasma (PRP) was further centrifuged at 1300g for 10 minutes (20°C) to sediment the platelets.
  • the supernatant was discarded and the pellet washed with a physiological salt solution (HEPES 5mM, NaHCO 3 12mM, NaCl 140mM, KH 2 PO 4 0.74mM, D-Glucose 5.6mM, KCl 2.82mM and BSA 20g/1, pH 7.4) to remove residual plasma.
  • a physiological salt solution HPES 5mM, NaHCO 3 12mM, NaCl 140mM, KH 2 PO 4 0.74mM, D-Glucose 5.6mM, KCl 2.82mM and BSA 20g/1, pH 7.4
  • the compound of the invention microcrystalline cellulose, lactose and cross-linked polyvinylpyrrolidone are sieved through a 500 micron sieve and blended in a suitable mixer.
  • the magnesium stearate is sieved through a 250 micron sieve and blended with the active blend.
  • the blend is compressed into tablets using suitable punches.
  • Compound of the invention 5.0mg
  • the compound of the invention, lactose and pregelatinised starch are blended together and granulated with water.
  • the wet mass is dried and milled.
  • the magnesium stearate and cross-linked polyvinylpyrrolidone are screened through a 250 micron sieve and blended with the granule.
  • the resultant blend is compressed using suitable tablet punches.
  • the compound of the invention and pregelatinised starch are screened through a 500 micron mesh sieve, blended together and lubricated with magnesium stearate, (meshed through a 250 micron sieve). The blend is filled into hard gelatine capsules of a suitable size.
  • Compound of the invention 5.0mg
  • the compound of the invention and lactose are blended together and granulated with a solution of polyvinylpyrrolidone.
  • the wet mass is dried and milled.
  • the magnesium stearate and cross-linked polyvinylpyrrolidone are screened through a 250 micron sieve and blended with the granules.
  • the resultant blend is filled into hard gelatine capsules of a suitable size.
  • the hydroxypropyl methylcellulose is dispersed in a portion of hot purified water together with the hydroxybenzoates and the solution is allowed to cool to room temperature.
  • the saccharin sodium flavours and sorbitol solution are added to the bulk solution.
  • the compound of the invention is dissolved in a portion of the remaining water and added to the bulk solution. Suitable buffers may be added to control the pH in the region of maximum stability.
  • the solution is made up to volume, filtered and filled into suitable containers.
  • Sodium chloride may be added to adjust the tonicity of the solution and the pH may be adjusted to that of maximum stability and/or to facilitate solution of the compound of the invention using dilute acid or alkali or by the addition of suitable buffer salts.
  • Antioxidants and metal chelating salts may also be included.
  • the solution is prepared, clarified and filled into appropriate sized ampoules sealed by fusion of the glass.
  • the injection is sterilised by heating in an autoclave using one of the acceptable cycles.
  • the solution may be sterilised by filtration and filled into sterile ampoules under aseptic conditions.
  • the solution may be packed under an inert atmosphere of nitrogen.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Dérivés d'acide acétique répondant à la formule (I), leurs dérivés pharmaceutiquement acceptables et leurs sels et solvates. Dans ladite formule, X1 et Y1 sont identiques ou différents et représentent CH ou N; X2 représente CH ou, lorsque X1 représente CH, peut également représenter N; Y2 représente N ou, lorsque Y1 représente N, peut également représenter CH; Z représente N ou N+R5; R1 représente un atome d'hydrogène ou un groupe hydroxyle, alkyle C¿1-4? ou 2,2,2-trifulorométhyle; R?2¿ représente un atome d'hydrogène ou, lorsque à la fois X1 et X2 représentent CH, peut également représenter un atome de fluor, de chlore ou de brome, ou un groupe alkyle C¿1-4; R?3 représente un atome d'hydrogène ou, lorsque à la fois Y1 et Y2 représentent N, peut également représenter un groupe alkyle C¿1-4? ou hydroxyméthyle; R?4¿ représente un atome d'hydrogène ou, lorsque Z représente N, R4 peut également représenter un groupe alkyle C¿1-4; R?5 représente un groupe alkyle C¿1-4? ou phénylalkyle C1-4; R?6¿ représente un groupe naphtyle; un groupe thiophényle; un groupe phényle non substitué; un groupe phényle substitué par alkyle C¿1-4?, alcoxy C1-4, phénylalcoxy C1-3, OH, halogène, où halogène est fluor, chlore, brome ou iode, CF3, phényle non substitué, phényle substitué par OH, pyridinyle, NR?7R8¿, NHSO¿2?R?7, CONR7R8¿ ou CO¿2R?7; un groupe alkyle C¿1-4? substitué par l'un au moins parmi naphtyle, phényle, OH ou CO2R?7¿; un groupe alcényle C¿2-4? substitué par l'un au moins parmi naphtyle, phényle, OH ou CO2R?7¿; ou un groupe cycloalkyle C¿5-7? éventuellement saturé; et R?7 et R8¿ sont identiques ou différents et représentent H ou alkyle C¿1-4? ou, conjointement avec l'atome d'azote auquel ils sont liés, forment un cycle saturé pentagonal ou heptagonal. Lesdits composés inhibent l'agrégation plaquettaire sanguine dépendante du fibrinogène.
PCT/EP1993/000100 1992-01-21 1993-01-15 Derives d'acide piperidineacetique servant d'inhibiteurs de l'agregation plaquettaire sanguine dependante du fibrinogene WO1993014077A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP5512158A JPH07503459A (ja) 1992-01-21 1993-01-15 酢酸誘導体
EP93902223A EP0623120A1 (fr) 1992-01-21 1993-01-15 Derives d'acide piperidineacetique servant d'inhibiteurs de l'agregation plaquettaire sanguine dependante du fibrinogene

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9201171.7 1992-01-21
GB929201171A GB9201171D0 (en) 1992-01-21 1992-01-21 Chemical compounds
GB9206004.5 1992-03-19
GB929206004A GB9206004D0 (en) 1992-03-19 1992-03-19 Chemical compounds

Publications (1)

Publication Number Publication Date
WO1993014077A1 true WO1993014077A1 (fr) 1993-07-22

Family

ID=26300182

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1993/000100 WO1993014077A1 (fr) 1992-01-21 1993-01-15 Derives d'acide piperidineacetique servant d'inhibiteurs de l'agregation plaquettaire sanguine dependante du fibrinogene

Country Status (7)

Country Link
EP (1) EP0623120A1 (fr)
JP (1) JPH07503459A (fr)
CN (1) CN1077953A (fr)
AU (1) AU3351293A (fr)
IL (1) IL104446A0 (fr)
MX (1) MX9300256A (fr)
WO (1) WO1993014077A1 (fr)

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030661A1 (fr) * 1994-05-04 1995-11-16 Bayer Aktiengesellschaft Amides aromatiques substitues d'acides thiocarboxyliques et leur utilisation comme herbicides
US5494922A (en) * 1993-06-28 1996-02-27 Zeneca Limited Allophanic acid derivatives
WO1996024583A1 (fr) * 1995-02-10 1996-08-15 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives de benzamidine et leur composition medicinale
US5556977A (en) * 1993-03-29 1996-09-17 Zeneca Limited Heterocyclic derivatives
US5563141A (en) * 1993-03-29 1996-10-08 Zeneca Limited Heterocyclic compounds
US5576334A (en) * 1993-06-28 1996-11-19 Zeneca Limited Acylurea derivatives
WO1997003072A1 (fr) * 1995-07-07 1997-01-30 Boehringer Mannheim Gmbh Derives nouveaux d'oxazolidinone, leur procede de preparation et medicaments contenant ces composes
US5612373A (en) * 1993-06-28 1997-03-18 Zeneca Limited Certain diacyl hydrazine derivatives
US5652242A (en) * 1993-03-29 1997-07-29 Zeneca Limited Heterocyclic derivatives
WO1997036899A1 (fr) * 1996-03-30 1997-10-09 Boehringer Mannheim Gmbh Nouveaux derives de l'oxazolidine, leur procede de production et medicaments les contenant
US5750754A (en) * 1993-03-29 1998-05-12 Zeneca Limited Heterocyclic compounds
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
EP0849261A1 (fr) * 1996-12-19 1998-06-24 Solvay Pharmaceuticals GmbH Dérivés d'acides pipérazinophényl- et pipérazinophényloxy-carboxyliques ainsi que procédés et produits intermédiaires de leur préparation et médicaments contenant ces composés
US5773442A (en) * 1995-02-10 1998-06-30 Yamanouchi Pharmaceutical Co., Ltd. Benzamidine derivatives and pharmaceutical composition containing them
WO1999020606A3 (fr) * 1997-10-23 1999-07-29 Uriach & Cia Sa J Nouvelles piperidines et piperazines utiles en tant qu'inhibiteurs de l'agregation plaquettaire
US6087379A (en) * 1996-08-28 2000-07-11 Sankyo Company, Limited Cyclic amine derivatives
RU2158263C2 (ru) * 1996-05-30 2000-10-27 Яманоути Фармасьютикал Ко., Лтд. Замещенное производное амидинобензола и фармацевтическая композиция на его основе
US6610708B1 (en) 1998-02-27 2003-08-26 Sankyo Company, Limited Cyclic amino compounds
USRE39263E1 (en) * 1994-05-04 2006-09-05 Bayer Aktiengesellschaft Substituted aromatic thiocarboxylic acid amides and their use as herbicides
WO2006088921A3 (fr) * 2005-02-16 2006-11-02 Schering Corp Piperazine-piperidines pyrazinyl substituees a activite antagoniste des cxcr3
WO2006088837A3 (fr) * 2005-02-16 2006-11-02 Schering Corp Piperazines heterocycliques substituees a activite antagoniste cxcr3
WO2006088836A3 (fr) * 2005-02-16 2006-11-02 Schering Corp Piperazine-piperidines a activite antagoniste cxcr3
WO2006091428A3 (fr) * 2005-02-16 2006-11-02 Schering Corp Pyrazinyl-piperazine-piperidines substitutees heteroaryle a activite antagoniste cxcr3
WO2006088919A3 (fr) * 2005-02-16 2006-11-02 Schering Corp Piperazine-piperidines pyridyl et phenyl substituees a activite antagoniste des cxcr3
US7592343B2 (en) 2004-09-20 2009-09-22 Xenon Pharmaceuticals Inc. Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
WO2010081851A1 (fr) 2009-01-14 2010-07-22 Genoscience Pharma Composés de pipéridin-4-ylpipérazine pour le traitement d'une infection à vhc
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7799789B2 (en) 2005-02-16 2010-09-21 Schering Corporation Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US7973052B2 (en) 2003-04-15 2011-07-05 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US8183239B2 (en) 2005-10-31 2012-05-22 Janssen Pharmaceutica Nv Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
US9908851B2 (en) * 2013-08-16 2018-03-06 Duke University 2-piperidinyl substituted N,3-dihydroxybutanamides
US10189786B2 (en) 2013-08-16 2019-01-29 Duke University Antibacterial compounds
US10597361B2 (en) 2010-09-03 2020-03-24 Duke University Ethynylbenzene derivatives
US10647664B2 (en) 2013-08-16 2020-05-12 Duke University Substituted hydroxamic acid compounds
US11021480B2 (en) 2018-08-29 2021-06-01 Morphic Therapeutic, Inc. Inhibiting (α-V)(β-6) integrin
US11040955B2 (en) 2017-02-28 2021-06-22 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
CN113075343A (zh) * 2020-01-04 2021-07-06 东莞市东阳光仿制药研发有限公司 一种羟胺及其盐的检测方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002245A1 (fr) * 1995-07-06 1997-01-23 Japan Tobacco Inc. Derives de benzamidoxime et leur utilisation a des fins medicinales

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4433152A (en) * 1981-05-25 1984-02-21 Nippon Chemiphar Co., Ltd. Amidinopiperidine derivatives
US4514416A (en) * 1981-02-27 1985-04-30 Torii & Co. Ltd. Amidine compound, process for producing same and anti-complement agent comprising same
EP0236164A1 (fr) * 1986-01-24 1987-09-09 Sanofi Dérivés des N alpha-arylsulfonylaminoacyl p-amidino-phénylalaninamides, leur procédé de préparation, leur application comme médicaments et leurs intermédiaires de synthèse
EP0537980A1 (fr) * 1991-10-16 1993-04-21 Glaxo Group Limited Dérivés de l'acide cyclohexan-acétique comme inhibiteurs de l'aggrégation de plaquettes fibrino-dépendants

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514416A (en) * 1981-02-27 1985-04-30 Torii & Co. Ltd. Amidine compound, process for producing same and anti-complement agent comprising same
US4433152A (en) * 1981-05-25 1984-02-21 Nippon Chemiphar Co., Ltd. Amidinopiperidine derivatives
EP0236164A1 (fr) * 1986-01-24 1987-09-09 Sanofi Dérivés des N alpha-arylsulfonylaminoacyl p-amidino-phénylalaninamides, leur procédé de préparation, leur application comme médicaments et leurs intermédiaires de synthèse
EP0537980A1 (fr) * 1991-10-16 1993-04-21 Glaxo Group Limited Dérivés de l'acide cyclohexan-acétique comme inhibiteurs de l'aggrégation de plaquettes fibrino-dépendants

Cited By (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652242A (en) * 1993-03-29 1997-07-29 Zeneca Limited Heterocyclic derivatives
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
US5750754A (en) * 1993-03-29 1998-05-12 Zeneca Limited Heterocyclic compounds
US5556977A (en) * 1993-03-29 1996-09-17 Zeneca Limited Heterocyclic derivatives
US5563141A (en) * 1993-03-29 1996-10-08 Zeneca Limited Heterocyclic compounds
US5728701A (en) * 1993-03-29 1998-03-17 Zeneca Limited Heterocyclic derivatives
US5576334A (en) * 1993-06-28 1996-11-19 Zeneca Limited Acylurea derivatives
US5494922A (en) * 1993-06-28 1996-02-27 Zeneca Limited Allophanic acid derivatives
US5981531A (en) * 1993-06-28 1999-11-09 Zeneca Limited Acid derivatives
US5760057A (en) * 1993-06-28 1998-06-02 Zeneca Limited Certain (piperidin-4-yl-alkanoyl)carbazoyl!-carboxy-phenoxy derivatives
US5612373A (en) * 1993-06-28 1997-03-18 Zeneca Limited Certain diacyl hydrazine derivatives
US6331507B1 (en) 1994-05-04 2001-12-18 Bayer Aktiengesellschaft Substituted aromatic thiocarboxylic acid amides and their use as herbicides
WO1995030661A1 (fr) * 1994-05-04 1995-11-16 Bayer Aktiengesellschaft Amides aromatiques substitues d'acides thiocarboxyliques et leur utilisation comme herbicides
USRE39263E1 (en) * 1994-05-04 2006-09-05 Bayer Aktiengesellschaft Substituted aromatic thiocarboxylic acid amides and their use as herbicides
US6451736B1 (en) 1994-05-04 2002-09-17 Bayer Aktiengesellschaft Substituted aromatic thiocarboxylic acid amides and their use as herbicides
US6077813A (en) * 1994-05-04 2000-06-20 Bayer Aktiengesellschaft Substituted aromatic thiocarboxylic acid amides and their use as herbicides
US6420316B1 (en) 1994-05-04 2002-07-16 Bayer Aktiengesellschaft Substituted aromatic thiocarboxylic acid amides and their use as herbicides
WO1996024583A1 (fr) * 1995-02-10 1996-08-15 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives de benzamidine et leur composition medicinale
US5773442A (en) * 1995-02-10 1998-06-30 Yamanouchi Pharmaceutical Co., Ltd. Benzamidine derivatives and pharmaceutical composition containing them
WO1997003072A1 (fr) * 1995-07-07 1997-01-30 Boehringer Mannheim Gmbh Derives nouveaux d'oxazolidinone, leur procede de preparation et medicaments contenant ces composes
WO1997036899A1 (fr) * 1996-03-30 1997-10-09 Boehringer Mannheim Gmbh Nouveaux derives de l'oxazolidine, leur procede de production et medicaments les contenant
RU2158263C2 (ru) * 1996-05-30 2000-10-27 Яманоути Фармасьютикал Ко., Лтд. Замещенное производное амидинобензола и фармацевтическая композиция на его основе
US6087379A (en) * 1996-08-28 2000-07-11 Sankyo Company, Limited Cyclic amine derivatives
US5843948A (en) * 1996-12-19 1998-12-01 Solvay Pharmaceuticals Gmbh Piperazinophenyl- and piperazinophenyloxycarboxylic acid derivatives, and processes and intermediates for their preparation and pharmaceutical compositions comprising them
EP0849261A1 (fr) * 1996-12-19 1998-06-24 Solvay Pharmaceuticals GmbH Dérivés d'acides pipérazinophényl- et pipérazinophényloxy-carboxyliques ainsi que procédés et produits intermédiaires de leur préparation et médicaments contenant ces composés
WO1999020606A3 (fr) * 1997-10-23 1999-07-29 Uriach & Cia Sa J Nouvelles piperidines et piperazines utiles en tant qu'inhibiteurs de l'agregation plaquettaire
CZ300821B6 (cs) * 1998-02-27 2009-08-19 Sankyo Company Limited Cyklické aminoslouceniny
US6610708B1 (en) 1998-02-27 2003-08-26 Sankyo Company, Limited Cyclic amino compounds
US7973052B2 (en) 2003-04-15 2011-07-05 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US7592343B2 (en) 2004-09-20 2009-09-22 Xenon Pharmaceuticals Inc. Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US8026360B2 (en) 2004-09-20 2011-09-27 Xenon Pharmaceuticals Inc. Substituted pyridazines as stearoyl-CoA desaturase inhibitors
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
WO2006088921A3 (fr) * 2005-02-16 2006-11-02 Schering Corp Piperazine-piperidines pyrazinyl substituees a activite antagoniste des cxcr3
JP2011126901A (ja) * 2005-02-16 2011-06-30 Schering Corp Ｃｘｃｒ３アンタゴニスト活性を有する、複素環で置換されたピペラジン
US7763616B2 (en) 2005-02-16 2010-07-27 Schering Corporation Piperazine-piperidines with CXCR3 antagonist activity
US7799789B2 (en) 2005-02-16 2010-09-21 Schering Corporation Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity
US7776862B2 (en) 2005-02-16 2010-08-17 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
US7868005B2 (en) 2005-02-16 2011-01-11 Schering Corporation Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity
US7868006B2 (en) 2005-02-16 2011-01-11 Schering Corporation Heterocyclic substituted piperazines with CXCR3 antagonist activity
US7879838B2 (en) 2005-02-16 2011-02-01 Schering Corporation Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity
WO2006088837A3 (fr) * 2005-02-16 2006-11-02 Schering Corp Piperazines heterocycliques substituees a activite antagoniste cxcr3
WO2006088836A3 (fr) * 2005-02-16 2006-11-02 Schering Corp Piperazine-piperidines a activite antagoniste cxcr3
US8207170B2 (en) 2005-02-16 2012-06-26 Schering Corporation Heterocyclic substituted piperazines with CXCR3 antagonist activity
WO2006091428A3 (fr) * 2005-02-16 2006-11-02 Schering Corp Pyrazinyl-piperazine-piperidines substitutees heteroaryle a activite antagoniste cxcr3
JP2008530218A (ja) * 2005-02-16 2008-08-07 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有する、ピリジルおよびフェニルで置換されたピペラジン−ピペリジン
WO2006088919A3 (fr) * 2005-02-16 2006-11-02 Schering Corp Piperazine-piperidines pyridyl et phenyl substituees a activite antagoniste des cxcr3
CN101163692B (zh) * 2005-02-16 2012-01-18 先灵公司 具有cxcr3拮抗活性的杂环取代的哌嗪
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
US8183239B2 (en) 2005-10-31 2012-05-22 Janssen Pharmaceutica Nv Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor
WO2010081851A1 (fr) 2009-01-14 2010-07-22 Genoscience Pharma Composés de pipéridin-4-ylpipérazine pour le traitement d'une infection à vhc
US10597361B2 (en) 2010-09-03 2020-03-24 Duke University Ethynylbenzene derivatives
US9908851B2 (en) * 2013-08-16 2018-03-06 Duke University 2-piperidinyl substituted N,3-dihydroxybutanamides
US10189786B2 (en) 2013-08-16 2019-01-29 Duke University Antibacterial compounds
US10647664B2 (en) 2013-08-16 2020-05-12 Duke University Substituted hydroxamic acid compounds
US11040955B2 (en) 2017-02-28 2021-06-22 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
US11046669B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
US11795167B2 (en) 2017-02-28 2023-10-24 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
US11827621B2 (en) 2017-02-28 2023-11-28 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
US12145935B2 (en) 2017-02-28 2024-11-19 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
US11021480B2 (en) 2018-08-29 2021-06-01 Morphic Therapeutic, Inc. Inhibiting (α-V)(β-6) integrin
US11739087B2 (en) 2018-08-29 2023-08-29 Morphic Therapeutic, Inc. Inhibiting (α-v)(β-6) integrin
CN113075343A (zh) * 2020-01-04 2021-07-06 东莞市东阳光仿制药研发有限公司 一种羟胺及其盐的检测方法
CN113075343B (zh) * 2020-01-04 2024-02-23 东莞市东阳光仿制药研发有限公司 一种羟胺及其盐的检测方法

Also Published As

Publication number Publication date
AU3351293A (en) 1993-08-03
MX9300256A (es) 1993-07-01
CN1077953A (zh) 1993-11-03
JPH07503459A (ja) 1995-04-13
IL104446A0 (en) 1993-05-13
EP0623120A1 (fr) 1994-11-09

Similar Documents

Publication Publication Date Title
WO1993014077A1 (fr) Derives d'acide piperidineacetique servant d'inhibiteurs de l'agregation plaquettaire sanguine dependante du fibrinogene
AP330A (en) Piperidine aectate derivatives.
EP1181017B1 (fr) Inhibiteur de metalloproteases
US6511993B1 (en) Metalloprotease inhibitors
JP4758609B2 (ja) γ−セクレターゼ阻害剤
EP1343761B1 (fr) Antagonistes piperidiniques de mch et leur utilisation dans le traitement de l'obesite
JP2004520347A (ja) Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
BRPI0612957A2 (pt) composto, processos de preparação de compostos, composição farmacêutica e usos de um composto
WO1993022303A1 (fr) Derives 1-piperazinacetiques utilises comme antagonistes de recepteur de fibrinogene
US6239126B1 (en) Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives
EP0537980A1 (fr) Dérivés de l'acide cyclohexan-acétique comme inhibiteurs de l'aggrégation de plaquettes fibrino-dépendants
EP0444945A2 (fr) Utilisation des composés spirocycliques comme antagonistes de l'oxytocin
US20040132710A1 (en) Lactams as tachkinin antagonists
JP4464280B2 (ja) エリスロポエチン産生促進剤
EP0799223B1 (fr) Derives d'acide piperidinacetiques agissant comme antagonistes de fibrinogene
JP4444375B2 (ja) 新規キノリン−およびナフタレンカルボキサミド、医薬組成物およびカルパインの阻害方法
JP4276070B2 (ja) 環状アミン化合物
AU2007258871B2 (en) Aryl- and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their application in therapeutics
US5998439A (en) Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
WO2000035875A1 (fr) Derives d'uree arylpiperidine et aryl-1,2,5,6-tetrahydropyridine presentant une activite de recepteur de 5ht1a
US5486527A (en) Anticholinergic agents
JP2002504082A (ja) アレルギー疾患の治療に有用な新規な置換されたｎ―メチル―ｎ―（４―（ピペリジン―１―イル）―２―（アリール）ブチル）ベンズアミド
US5607950A (en) Muscarinic receptor antagonists
DE69014903T2 (de) Disubstituierte piperidine und pyrrolidine als anticholinergische mittel.
JP2001019672A (ja) 掻痒症の治療用の新規な４−アリールピペリジン誘導体

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1993902223

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1994 256357

Date of ref document: 19940726

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1993902223

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1993902223

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载